cystic fibrosis

Oct 22, 2019

The US FDA today has given its nod to Trikafta (elexacaftor/ivacaftor/tezacaftor) of Vertex Pharmaceuticals, the first of its kind triple combination therapy for the patients with cystic fibrosis. The drug, Trikafta, has been approved for patients of age 12 years and older who have at least one F508del mutation...

Sep 27, 2019

Cystic fibrosis (CF) manifests as a clinical syndrome characterized by chronic sinopulmonary infection as well as by gastrointestinal, nutritional, and other abnormalities. Lung damage secondary to chronic infection is the main determinant of morbidity and mortality in individuals with cystic fibrosis. CF indivi...

Mar 19, 2019

A New Approach to treat Cystic Fibrosis Researchers at the University of Illinois in Champaign have found that anti-fungal drug amphotericin that helps lung cells to fight chronic bacterial lung infection can help in treating Cystic Fibrosis- a genetic disorder that causes serious damages to lungs. The finding ...

Aug 21, 2018

Kalydeco, the first Cystic Fibrosis drug of Vertex, got approved for infants The Food and Drug Administration has cleared Kalydeco drug of Vertex Pharmaceuticals for infants aged 12 to under 24 months. The approved drug treats the underlying cause of cystic fibrosis in children of this age with at least one mutatio...

Aug 17, 2018

Alnylam’s Onpattro Receives First-Ever US FDA Approval for Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults US FDA approved Alnylam’s Onpattro (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneurop...

Dec 30, 2014

Gene Therapy’s “expanding” role in Respiratory disorders! About Respiratory disorders Respiratory disorders encompasses pathological conditions affecting the organs and tissues that make gas exchange possible in higher organisms, and includes conditions of the upper respiratory tract, trachea, bronchi, bronchioles...